Continuous glucose monitoring system (Guardian Connect®, Medtronic)
10-26-2020 | Innovations non pharmaceutiques
It is estimated that approximately 70% of type 1 diabetics (T1Ds) do not achieve the recommended HbA1c (glycosylated hemoglobin) targets. In Canada, the Guardian Connect® continuous glucose monitoring (CGM) technology is approved for the management of diabetes in patients aged 3 years and older. Approval is granted as a complement to fingertip blood glucose testing. Treatment adjustments should thus be based on capillary blood glucose measurements, not on those obtained with the Guardian’s sensor.
It was in this context that INESSS was mandated by the Bureau de l’innovation to assess the relevance of public coverage of the Guardian Connect® continuous glucose monitoring (CGM) technology.
Considering the available information, INESSS does not recommend public coverage of the Guardian Connect® continuous glucose monitor, as its therapeutic value has not been demonstrated.